Clinical

Dataset Information

0

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer


ABSTRACT: TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

DISEASE(S): Adenocarcinoma,Tnbc - Triple-negative Breast Cancer,Pancreatic Adenocarcinoma,Triple Negative Breast Neoplasms,Colorectal Cancer,Non Small Cell Lung Cancer,Mesothelioma,Triple Negative Breast Cancer,Pancreatic Cancer,Breast Neoplasms,Neoplasms,Ovarian Cancer,Mesothelioma Peritoneum,Mesotheliomas Pleural,Colorectal Neoplasms,Mesothelioma, Malignant,Cystadenocarcinoma, Serous,Ovarian Neoplasms,Ovarian Serous Adenocarcinoma,Pancreatic Neoplasms,Cholangiocarcinoma,Ovarian Adenocarcinoma

PROVIDER: 2740481 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-02-14 | GSE160311 | GEO
2016-11-03 | MODEL1604100000 | BioModels
2018-08-30 | GSE112066 | GEO
2023-12-29 | GSE229921 | GEO
2019-11-12 | PXD008258 | Pride
2021-07-13 | GSE154538 | GEO
2021-07-13 | GSE154536 | GEO
2011-01-01 | E-GEOD-19778 | biostudies-arrayexpress
2023-03-31 | MSV000091606 | MassIVE
| 61464 | ecrin-mdr-crc